Hyperuricosuria

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease

Retrieved on: 
Tuesday, September 8, 2020
Uric acid, Medical specialties, Inborn errors of purine-pyrimidine metabolism, Clinical medicine, Medicine, Hyperuricemia, Gout, Uricemia, Chronic kidney disease, Probenecid, Hyperuricosuria

Increased uric acid excretion in the urine and hyperuricemia are also associated with kidney stone formation and kidney damage.

Key Points: 
  • Increased uric acid excretion in the urine and hyperuricemia are also associated with kidney stone formation and kidney damage.
  • CKD patients with hyperuricemia and gout are often not optimally managed due to limitations of available therapies, including decreased tolerability, dose restrictions, drug-drug interactions, and contraindications.
  • Allena expects to report initial clinical data in the fourth quarter of 2020, subject to the impact of COVID-19.
  • Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.